All data are based on the daily closing price as of September 6, 2024
m
Mycenax Biotech
4726.TWO
1.48 USD
0.02
+1.37%
Overview
Last close
1.48 usd
Market cap
304.85M usd
52 week high
1.91 usd
52 week low
1.06 usd
Target price
N/A usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
16.8483
Price/Book Value
4.3635
Enterprise Value
317.25M usd
EV/Revenue
17.6115
EV/EBITDA
-95.509
Key financials
Revenue TTM
18.01M usd
Gross Profit TTM
-3.60M usd
EBITDA TTM
-7.61M usd
Earnings per Share
-0.08 usd
Dividend
N/A usd
Total assets
3.63B usd
Net debt
367.01M usd
About
Mycenax Biotech Inc. develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, Asia, and the United States. The company develops monoclonal antibodies, bi-specific antibodies, fc-fusion proteins, recombinant proteins, peptides, protein conjugates (non-toxin), antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), as well as plasmids and DNA vaccines. It also provides process development solutions, including development of production cell lines, upstream and downstream process development, process scale-up, formulation development, and analytical methods; in-house analytical services; GMP manufacturing services, such as drug substance and products manufacturing, and cell banking; and manufacturing technologies. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.